MannKind | MNKD - Net Income


MannKind reported $-15.95M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Adma Biologics USD 49.38M 12.95M Dec/2025
BioCryst Pharmaceuticals USD 245.84M 232.95M Dec/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Halozyme Therapeutics USD -141.59M 316.82M Dec/2025
Insmed USD -328.48M 41.54M Dec/2025
Karyopharm Therapeutics USD -102.2M 71.42M Dec/2025
MacroGenics USD -14.16M 30.98M Dec/2025
MannKind USD -15.95M 23.93M Dec/2025
Merck USD 2.96B 2.82B Dec/2025
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Novavax USD 17.53M 219.91M Dec/2025
Novo Nordisk DKK 4.03B 25.01B Jun/2025
Pfizer USD -1.65B 5.19B Dec/2025
Sanofi EUR 1.61B 2.42B Mar/2026
Xencor USD -6.65M 626K Dec/2025